Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Barbro Linderholm

Universitetslektor, adjungerad

Barbro Linderholm
Universitetslektor, adjungerad
barbro.linderholm@oncology.gu.se
+46 31-342 1000

Postal Address: Jubileumskliniken, Sahlgrenska universitetssjukhuset, 41345 Göteborg
Visiting Address: Blå stråket 2, Jubileumskliniken, Sahlgrenska universitetssjukhuset , 41345 Göteborg


Department of Oncology at Institute of Clinical Sciences (More Information)
Sahlgrenska Universitetssjukhuset
413 45 Göteborg
0313428503
Visiting Address: Blå stråket 2 SU/Jubileusklin , 413 45 Göteborg

Latest publications

Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer.
Alexios Matikas, Sara Margolin, Mats Hellström, Hemming Johansson, Nils-Olof Bengtsson et al.
Breast cancer research and treatment, Journal article 2018
Journal article

The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2−) breast cancer: When might multigene assays be of value?
Matti Aapro, Michelino De Laurentiis, Dan Rea, Juan Enrique Bargallo Rocha, Roberto Elizalde et al.
Breast, Journal article 2017
Journal article

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00
M. Colleoni, K. P. Gray, S. Gelber, I. Lang, B. Thurlimann et al.
Journal of Clinical Oncology, Journal article 2016
Journal article

Transcriptional profiling of breast cancer metastases identifies liver metastasis-selective genes associated with adverse outcome in luminal A primary breast cancer.
Siker Kimbung, Ida Johansson, Anna Danielsson, Srinivas Veerla, Suzanne Egyhazi Brage et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, Journal article 2016
Journal article

Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer.
Henrik J Johansson, Betzabe C Sanchez, Jenny Forshed, Olle Stål, Helena Fohlin et al.
Clinical proteomics, Journal article 2015
Journal article

Showing 1 - 10 of 29

2020

2018

Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer.
Alexios Matikas, Sara Margolin, Mats Hellström, Hemming Johansson, Nils-Olof Bengtsson et al.
Breast cancer research and treatment, Journal article 2018
Journal article

2017

The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2−) breast cancer: When might multigene assays be of value?
Matti Aapro, Michelino De Laurentiis, Dan Rea, Juan Enrique Bargallo Rocha, Roberto Elizalde et al.
Breast, Journal article 2017
Journal article

2016

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00
M. Colleoni, K. P. Gray, S. Gelber, I. Lang, B. Thurlimann et al.
Journal of Clinical Oncology, Journal article 2016
Journal article

Transcriptional profiling of breast cancer metastases identifies liver metastasis-selective genes associated with adverse outcome in luminal A primary breast cancer.
Siker Kimbung, Ida Johansson, Anna Danielsson, Srinivas Veerla, Suzanne Egyhazi Brage et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, Journal article 2016
Journal article

2015

Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer.
Henrik J Johansson, Betzabe C Sanchez, Jenny Forshed, Olle Stål, Helena Fohlin et al.
Clinical proteomics, Journal article 2015
Journal article

Showing 1 - 10 of 29

Page Manager: Katarina Olinder Eriksson|Last update: 3/28/2013
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?